---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-090892"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:09:04.432210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8

## Summary
- Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.
- Cash $0.75M at June 30; raised $7.5M in July direct offering.
- FDA ADCOM for NurOwn BLA scheduled Sep 27; PDUFA target Dec 8, 2023.
- Appointed Dr. Bob Dagher as Chief Development Officer and Dr. Kirk Taylor as Chief Medical Officer.
- Biomarker data from Phase 3 showed NurOwn lowered neurofilament light, a predictor of clinical benefit in ALS.

## SEC filing metadata
- accession: 0001104659-23-090892
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/0001104659-23-090892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/tm2323640d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-090892
- JSON: https://secwatch.observer/filing/0001104659-23-090892.json
- Plain text: https://secwatch.observer/filing/0001104659-23-090892.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $5.3 million, EPS Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023 was approximately $5.3 million
  - EPS: Net loss per share for the three months ended June 30, 2023 and 2022 was $0.13
  - Result: reported results
  source text: BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/0001104659-23-090892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.